France‑based startup Ocean Diagnostics reported a pilot clinical evaluation in which its rapid bloodstream pathogen ID test matched conventional blood cultures at 100% and strongly correlated with mass spectrometry. The test combines high‑volume sample prep, pan‑bacterial PCR and nanopore sequencing to analyze viable bacteria from up to 10 mL of whole blood and currently returns results in about five hours. Principal investigator Antoine Dewitte and Bordeaux University Hospital compared Ocean Dx with routine blood culture and MALDI‑TOF. Ocean Diagnostics plans clinical trials in 2026 to support CE marking and pursue FDA clearance, targeting a commercial launch in 2028. If validated in larger trials, the platform could compress time to pathogen identification and reshape antimicrobial stewardship by reducing empiric, broad‑spectrum therapy.